During the past decade, Winston-Salem Dermatology and Surgery Center, PLLC conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Winston-Salem Dermatology and Surgery Center, PLLC" are "Dermatitis, Atopic" (2 trials), "Dermatitis" (1 trials), "Eczema" (1 trials), "Genetic Diseases, Inborn" (1 trials) and "Hypersensitivity" (1 trials). Many other conditions were trialed in "Winston-Salem Dermatology and Surgery Center, PLLC" in a lesser frequency.

Most popular intervention types in "Winston-Salem Dermatology and Surgery Center, PLLC" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Abrocitinib 100 mg" (1 trials), "Abrocitinib 200 mg" (1 trials), "Dupilumab" (1 trials), "Injectable Placebo" (1 trials) and "Oral Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Winston-Salem Dermatology and Surgery Center, PLLC" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Winston-Salem Dermatology and Surgery Center, PLLC". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Winston-Salem Dermatology and Surgery Center, PLLC, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Winston-Salem Dermatology and Surgery Center, PLLC, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".